Zoster vaccine live

Pharmacotherapy

Volumn 27, Issue 7, 2007, Pages 1013-1019

  Kockler, Denise R ^a,c   McCarthy, Michelle W ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Herpes zoster vaccine; Shingles; Varicella zoster virus vaccine; Zostavax

Indexed keywords

CORTICOSTEROID; PLACEBO; PREDNISONE; VARICELLA ZOSTER VACCINE;

ADULT; AGED; ANAPHYLAXIS; ASTHENIA; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG APPROVAL; DRUG MEGADOSE; FEVER; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; GOODPASTURE SYNDROME; HEADACHE; HERPES ZOSTER; HUMAN; INJECTION SITE REACTION; POSTHERPETIC NEURALGIA; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATIC POLYMYALGIA; RHINITIS; SKIN DISEASE; UNITED STATES; VACCINE PRODUCTION; VARICELLA ZOSTER VIRUS;

CLINICAL TRIALS; HERPES ZOSTER; HERPES ZOSTER VACCINE; HERPESVIRUS 3, HUMAN; HUMANS; VACCINES, ATTENUATED;

EID: 34250863766     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.7.1013     Document Type: Review

References (33)

1. Gnann JW, Whitley RJ. Herpes zoster. N Engl J Med 2002;347:340-6.
2. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995;155:1605-9.
3. Ragozzino MW, Melton LJ III, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982;61:310-16.
4. Schmader K. Herpes zoster in older adults. Clin Infect Dis 2001;32:1481-6.
5. Mounsey AL, Matthew LG, Slawson DC. Herpes zoster and postherpetic neuralgia: prevention and management. Am Fam Physician 2005;72:1075-80.
6. Merck & Co., Inc. Zostavax (zoster vaccine live [Oka/Merck]) package insert. Whitehouse Station, NJ; 2006.
7. Centers for Disease Control and Prevention. CDC's advisory committee recommends "shingles" vaccination [press release]. Available from http://www.cdc.gov/od/media/pressrel/r061026.htm. Accessed October 31, 2006.
8. Tenser RB, Dworkin RH. Herpes zoster and prevention of postherpetic neuralgia: beyond antiviral therapy. Neurology 2005;65:349-50.
9. Grabenstein JD. ImmunoFacts: vaccines and immunologic drugs. St. Louis, MO: Wolters Kluwer Health, 2007:318-26.
10. Gilden DH. Varicella-zoster vaccine - grown ups need it, too. N Engl J Med 2005;352:2344-5.
11. Trannoy E, Berger R, Holländer G, et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine 2000;18:1700-6.
12. Berger R, Amstutz I, Just M, Just V, Leuscher D. Booster vaccinations of healthy adults with VZV antibody but without a VZV-specific cell-mediated immune response. Antiviral Res 1985;1(suppl):267-71.
13. Levin MJ, Barber D, Goldblatt E, et al. Use of live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis 1998;178(suppl 1):S109-12.
14. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271-84.
15. Breuer J. Vaccination to prevent varicella and shingles. J Clin Pathol 2001;54:743-7.
16. Levin MJ, Smith JG, Kaufhold RM, et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 2003;188:1336-44.
17. Smith JG, Levin M, Vessey R, et al. Measurement of cell-mediated immunity with a varicella-zoster virus-specific interferon-γ ELISPOT assay: responses in an elderly population receiving a booster immunization. J Med Virol 2003;70(suppl):S38-41.
18. Levin MJ, Murray M, Rotbart HA, Zerbe GO, White CJ, Hayward AR. Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis 1992;166:253-9.
19. Coplan PM, Schmader K, Nikas A, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 2004;5:344-56.
20. Huges P, LaRussa P, Pearce JM, Lepow M, Steinberg S, Gershon A. Transmission of varicella-zoster virus from a vaccinee with leukemia, demonstrated by polymerase chain reaction. J Pediatr 1994;124:932-5.
21. Tsolia M, Gershon AA, Steinberg SP, Gelb L. Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. J Pediatr 1990;116:184-9.
22. LaRussa P, Steinberg S, Maurice F, Gershon A. Transmission of vaccine strain varicella-zoster virus from a healthy adult with vaccine-associated rash to susceptible household contacts. J Infect Dis 1997;176:1072-5.
23. Salzman M, Sharrar R, Steinberg S, LaRussa P. Transmission of varicella vaccine virus from a healthy 12-month-old child to his pregnant mother. J Pediatr 1997;131:151-4.
24. Brunell PA, Argaw T. Chickenpox attributable to a vaccine virus contacted from a vaccinee with zoster. Pediatrics 2000;106:e28. Available from http://pediatrics.aappublications.org/cgi/content/abstract/106/2/e28.
25. Grossberg R, Harpaz R, Rubtcova E, Loparev V, Seward JF, Schmid DS. Secondary transmission of varicella vaccine virus in a chronic care facility for children. J Pediatr 2006;148:842-4.
26. Sharrar RG, LaRussa P, Galea SA, et al. The postmarketing safety profile of varicella vaccine. Vaccine 2001;19:916-23.
27. Atkinson WL, Pickering LK, Schwartz B, Weniger BG, Iskander JK, Watson JC. General recommendations on immunization. Recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep Recomm Rep 2006;55(RR-15):1-56.
28. Centers for Disease Control and Prevention. CDC's shingles vaccine patient information sheet. Available from: http://www.cdc.gov/nip/publications/ VIS/vis-shingles.pdf. Accessed March 5, 2007.
29. Anonymous. Zostavax coverage under part D sets precedent for new vaccines. FDC reports: the pink sheet 2006;68(36):20-1.
30. Koplan JP, Harpaz R. Shingles vaccine: effective and costly or cost-effective? Ann Intern Med 2006;145:386-7.
31. Johnson A. Panel backs shingles vaccine for prevention in older adults. Wall Street Journal. October 26, 2006:D4.
32. Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006;145:317-25.
33. Pellissier J, and the Zostavax Outcomes Research Team. Evaluation of the cost-effectiveness in the U.S. of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Presented at the advisory committee on immunization practices meeting, Atlanta, GA, June 30, 2006. Available from http://www.cdc.gov/nip/ACIP/slides/jun06/shingles-1-pellissier.pdf. Accessed July 10, 2006.